Thyroid hormone receptor-beta (THR-β) agonists, which lower triglycerides and cholesterol while conferring hepatic benefits, had emerged as a primary strategy for addressing dyslipidemia, obesity, and hepatic steatosis (51). This evidence concerns the gene THRB and Hepatic steatosis.